{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:14:26Z","timestamp":1781216066206,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Subcutaneous panniculitis T-cell lymphoma (SPTCL) is a rare, cytotoxic T-cell lymphoma with which some patients have accompanying hemophagocytic syndrome (HPS). There is currently no standard treatment regimen. In the past, the most commonly used treatment was multidrug chemotherapy. In contrast, numerous case reports or small series suggest that immunosuppressive drugs could also be effective for some patients. Since this NHL subtype is extremely rare in children and adolescents, to improve the understanding of this disease and standardize its rational treatment, we retrospectively summarized the treatment regimens of 18 pathologically diagnosed children with SPTCL to compare the clinical efficacy of multidrug chemotherapy and immunomodulatory therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of onset was 11.1\u00a0years. Painless subcutaneous nodules or skin patchy lesions were found in all patients, most commonly involving the lower extremities and\/or trunk. Before January 1, 2019, the treatment was mainly chemotherapy, and 10 patients were initially treated with chemotherapy, among whom was one patient who progressed during initial treatment, was voluntarily discharged and was subsequently lost to follow-up, one patient who died of disease progression, and the remaining 8 patients who all achieved sustained remission, with a complete remission (CR) rate of 80% (8\/10). Corticosteroids combined with cyclosporine A or ruxolitinib were the most common initial immunosuppressive agents at our center after January 1, 2019 and had a CR rate of 71.4% (5\/7). In addition, 1 patient achieved partial remission (PR) during follow-up, and one had autologous hematopoietic stem cell transplantation (AHSCT) after 4\u00a0months of drug withdrawal. There were 7 patients (38.9%, one case in chemotherapy group and six cases in immunotherapy group) with HPS and 4\/5 screened patients (80%) with positive <jats:italic>HAVCR2<\/jats:italic> gene mutations. The median follow-up was 17\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The prognosis of SPTCL is relatively good. Previous multi-drug and long-term chemotherapy treatment has clear efficacy, and recent immunomodulatory therapy as pre-chemotherapy therapy can also benefit patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02575-4","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T04:12:33Z","timestamp":1670818353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A retrospective study of 18 children with subcutaneous panniculitis-like T-cell lymphoma: multidrug combination chemotherapy or immunomodulatory therapy?"],"prefix":"10.1186","volume":"17","author":[{"given":"Yanlong","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunju","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-8567","authenticated-orcid":false,"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"issue":"4","key":"2575_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjd.13053","volume":"171","author":"E Guenova","year":"2014","unstructured":"Guenova E, Schanz S, Hoetzenecker W, DeSimone JA, Mehra T, Voykov B, Urosevic-Maiwald M, Berneburg M, Dummer R, French LE, et al. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. Br J Dermatol. 2014;171(4):891\u20134. https:\/\/doi.org\/10.1111\/bjd.13053.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2575_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1309\/AJCPVZYB19NEDXXZ","volume":"143","author":"NA Brown","year":"2015","unstructured":"Brown NA, Ross CW, Gudjonsson JE, Wale D, Pawarode A, Maillard I, Hristov AC. Subcutaneous panniculitis like T-cell lymphoma with bone marrow involvement. Am J Clin Pathol. 2015;143(2):265\u201373. https:\/\/doi.org\/10.1309\/AJCPVZYB19NEDXXZ.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2575_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1182\/blood-2007-040087288","volume":"111","author":"R Willemze","year":"2008","unstructured":"Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC cutaneous Lymphoma group study of 83 cases. Blood. 2008;111(2):838\u201345. https:\/\/doi.org\/10.1182\/blood-2007-040087288.","journal-title":"Blood"},{"key":"2575_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5021\/ad.2011.23.3.329","volume":"23","author":"DW Lee","year":"2011","unstructured":"Lee DW, Yang JH, Lee SM, Won CH, Chang S, Lee MW, Choi JH, Moon KC. Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 Korean patients. Ann Dermatol. 2011;23:329\u201337. https:\/\/doi.org\/10.5021\/ad.2011.23.3.329.","journal-title":"Ann Dermatol"},{"key":"2575_CR5","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1097\/PAS.0b013e31817a9081","volume":"32","author":"YY Kong","year":"2008","unstructured":"Kong YY, Dai B, Kong JC, Zhou XY, Lu HF, Shen L, Du X, Shi DR. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO- EORTC classification. Am J Surg Pathol. 2008;32:1495\u2013502. https:\/\/doi.org\/10.1097\/PAS.0b013e31817a9081.","journal-title":"Am J Surg Pathol"},{"key":"2575_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/cas.12439","volume":"148","author":"SR Hoque","year":"2003","unstructured":"Hoque SR, Child FJ, Whittaker SJ, Ferreira S, Orchard G, Jenner K, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of six patients. Br J Dermatol. 2003;148:516\u201325. https:\/\/doi.org\/10.1111\/cas.12439.","journal-title":"Br J Dermatol"},{"key":"2575_CR7","doi-asserted-by":"publisher","first-page":"201836","DOI":"10.1155\/2014\/201836","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Raina V. Successful treatment of disseminated subcutaneous panniculitis- like T-cell lymphoma with single agent oral cyclosporine as a first line therapy. Case Rep Dermatol Med. 2014;2014:201836. https:\/\/doi.org\/10.1155\/2014\/201836.","journal-title":"Case Rep Dermatol Med"},{"issue":"3","key":"2575_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4143\/crt.2014.46.3.312","volume":"46","author":"WS Lee","year":"2014","unstructured":"Lee WS, Hwang JH, Kim MJ, Go SI, Lee A, Song HN, Lee MJ, Kang MH, Kim HG, Lee JH. Cyclosporine A as a primary treatment for panniculitis-like T Cell lymphoma: a case with a long-term remission. Cancer Res Treat. 2014;46(3):312\u20136. https:\/\/doi.org\/10.4143\/crt.2014.46.3.312.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"2575_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00277-016-2615-0","volume":"95","author":"CC Chen","year":"2016","unstructured":"Chen CC, Teng CL, Yeh SP. Relapsed and refractory panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review. Ann Hematol. 2016;95(5):837\u201340. https:\/\/doi.org\/10.1007\/s00277-016-2615-0.","journal-title":"Ann Hematol"},{"key":"2575_CR10","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768\u201385. https:\/\/doi.org\/10.1182\/blood-2004-09-3502.","journal-title":"Blood"},{"key":"2575_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331. https:\/\/doi.org\/10.1002\/pbc.21039.","journal-title":"Pediatr Blood Cancer"},{"key":"2575_CR12","volume-title":"CTEP: NCI guidance on CTC terminology applications","author":"National Cancer Institute","year":"2006","unstructured":"National Cancer Institute. CTEP: NCI guidance on CTC terminology applications. Bethesda: National Cancer Institute; 2006."},{"issue":"5","key":"2575_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of imaging Subcommittee of International Harmonization project in lymphoma. J Clin Oncol. 2007;25(5):571\u20138. https:\/\/doi.org\/10.1200\/JCO.2006.08.2305.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2575_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/11311060-000000000-00000","volume":"11","author":"S Soylu","year":"2010","unstructured":"Soylu S, G\u00fcl U, Kili\u00e7 A, Ok\u00e7u-Heper A, Kuzu I, G\u00f6nen-Minareci B. A case with an indolent course of subcutaneous panniculitis-like T-cell lymphoma demonstrating Epstein-Barr virus positivity and simulating dermatitis artefacta. Am J Clin Dermatol. 2010;11(2):147\u201350. https:\/\/doi.org\/10.2165\/11311060-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"2575_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1097\/00000478-199807000-00010","volume":"22","author":"KE Salhany","year":"1998","unstructured":"Salhany KE, Macon WR, Choi JK, Elenitsas R, Lessin SR, Felgar RE, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha\/beta and gamma\/delta subtypes. Am J Surg Pathol. 1998;22(7):881\u201393. https:\/\/doi.org\/10.1097\/00000478-199807000-00010.","journal-title":"Am J Surg Pathol"},{"key":"2575_CR16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/pbc.24462","volume":"60","author":"AR Huppmann","year":"2013","unstructured":"Huppmann AR, Xi L, Raffeld M, Pittaluga S, Jaffe ES. Subcutaneous panniculitis- like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential. Pediatr Blood Cancer. 2013;60:1165\u201370. https:\/\/doi.org\/10.1002\/pbc.24462.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2575_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","volume":"3","author":"C Polprasert","year":"2019","unstructured":"Polprasert C, Takeuchi Y, Kakiuchi N, Yoshida K, Assanasen T, Sitthi T, et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Adv. 2019;3(4):588\u201395. https:\/\/doi.org\/10.1182\/bloodadvances.2018028340.","journal-title":"Blood Adv"},{"issue":"6","key":"2575_CR18","doi-asserted-by":"publisher","first-page":"e28302","DOI":"10.1002\/pbc.28302","volume":"67","author":"O Wegehaupt","year":"2020","unstructured":"Wegehaupt O, Gro\u03b2 M, Wehr C, Marks R, Schmitt-Graeff A, Uhl M, Lorenz M, Schwarz K, Kratz C, Niemeyer C, et al. TIM-3 deficiency presenting with two clonally unrelated episodes of mesenteric and subcutaneous panniculitis-like T- cell lymphoma and hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2020;67(6):e28302. https:\/\/doi.org\/10.1002\/pbc.28302.","journal-title":"Pediatr Blood Cancer"},{"key":"2575_CR19","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","volume":"50","author":"T Gayden","year":"2018","unstructured":"Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic syndrome. Nat Genet. 2018;50:1650\u20137. https:\/\/doi.org\/10.1038\/s41588-018-0251-4.","journal-title":"Nat Genet"},{"key":"2575_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","volume":"3","author":"C Polprasert","year":"2019","unstructured":"Polprasert C, Takeuchi Y, Kakiuchi N, Yoshida K, Assanasen T, Sitthi W, Bunworasate U, Pirunsarn A, Wudhikarn K, Lawasut P, et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T cell lymphoma. Blood Adv. 2019;3:588\u201395. https:\/\/doi.org\/10.1182\/bloodadvances.2018028340.","journal-title":"Blood Adv"},{"key":"2575_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0251-4","author":"T Gayden","year":"2018","unstructured":"Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet. 2018. https:\/\/doi.org\/10.1038\/s41588-018-0251-4.","journal-title":"Nat Genet"},{"key":"2575_CR22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003811","author":"G Sonigo","year":"2020","unstructured":"Sonigo G, Battistella M, Beylot-Barry M, Ingen-Housz-Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Soci\u00e9 G, et al. HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T- cell lymphoma. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2019003811.","journal-title":"Blood"},{"key":"2575_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","volume":"111","author":"R Willemze","year":"2008","unstructured":"Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83. Blood. 2008;111:838\u201345. https:\/\/doi.org\/10.1182\/blood-2007-04-087288.","journal-title":"Blood"},{"key":"2575_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5021\/ad.2011.23.3.329","volume":"23","author":"D-W Lee","year":"2011","unstructured":"Lee D-W, Yang J-H, Lee S-M, Won C-H, Chang S, Lee M-W, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 Korean patients. Ann Dermatol. 2011;23:329\u201337. https:\/\/doi.org\/10.5021\/ad.2011.23.3.329.","journal-title":"Ann Dermatol"},{"key":"2575_CR25","unstructured":"Musick SR, Lynch DT. Subcutaneous panniculitis like T-cell lymphoma. Elsevier; 1600 John F. Kennedy Blvd; Ste. 1600; Philadelphia, PA 19103-2899: StatPearls Publishing. 2022."},{"issue":"6","key":"2575_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3109\/08880018.2014.896062","volume":"31","author":"K Nagai","year":"2014","unstructured":"Nagai K, Nakano N, Iwai T, Iwai A, Tauchi H, Ohshima K, Ishii E. Pediatric subcutaneous panniculitis-like T-cell lymphoma with favorable result by immunosuppressive therapy: a report of two cases. Pediatr Hematol Oncol. 2014;31(6):528\u201333. https:\/\/doi.org\/10.3109\/08880018.2014.896062.","journal-title":"Pediatr Hematol Oncol"},{"key":"2575_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/10428190601078456","volume":"48","author":"P Rojnuckarin","year":"2007","unstructured":"Rojnuckarin P, Nakorn TN, Assanasen T, Wannakrairot P, Intragumtornchai T. Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2007;48:560\u20133. https:\/\/doi.org\/10.1080\/10428190601078456.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2575_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2340\/00015555-2543","volume":"97","author":"D Michonneau","year":"2017","unstructured":"Michonneau D, Petrella T, Ortonne N, Ingen-Housz-Oro S, Franck N, Barete S, Battistella M, Beylot-Barry M, Vergier B, Maynadi\u00e9 M, et al. Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol. 2017;97(3):358\u201364. https:\/\/doi.org\/10.2340\/00015555-2543.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"2575_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.4103\/ijdvl.IJDVL_747_18","volume":"85","author":"R Aragon-Miguel","year":"2019","unstructured":"Aragon-Miguel R, Calleja-Algarra A, Velasco-Tamarize V, Garrido M, Ortiz- Romero P, Maro\u00f1as-Jim\u00e9 Nez N. Is cyclosporine a good option for the treatment of subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic syndrome. Indian J Dermatol Venereol Leprol. 2019;85(6):656\u20139. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_747_18.","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02575-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02575-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02575-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T22:13:33Z","timestamp":1671142413000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02575-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2575"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02575-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent to participate in the program.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All other authors declare no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}